Emily Bergsland
艾米丽·伯格斯兰
MD
Professor of Medicine; Chief of Gastrointestinal Oncology医学教授；胃肠肿瘤科主任
👥Biography 个人简介
Dr. Emily Bergsland leads the UCSF NET program and is a nationally recognized expert in GI neuroendocrine tumors. She has played a central role in developing and evaluating somatostatin analogues and PRRT, and serves on multiple national guideline committees shaping NET clinical standards.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
PRRT and Somatostatin Analogue Research
Spearheaded UCSF's participation in landmark PRRT trials including NETTER-1, and advanced evidence-based use of somatostatin analogues for tumor control in metastatic NET.
NET Clinical Trials Infrastructure
Built a comprehensive NET clinical trials program at UCSF, facilitating access to novel therapeutics and contributing to multicenter cooperative group studies across the USA.
Representative Works 代表性著作
177Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1): contribution as US site PI
New England Journal of Medicine (2017)
Pivotal trial demonstrating Lu-177 PRRT superiority over high-dose octreotide LAR, resulting in FDA approval and transforming midgut NET treatment.
Neuroendocrine tumors: review of current guidelines
Journal of the National Comprehensive Cancer Network (2020)
Contributed to NCCN NET guideline development, synthesizing evidence to define algorithmic treatment recommendations for clinical practice.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 艾米丽·伯格斯兰 的研究动态
Follow Emily Bergsland's research updates
留下邮箱，当我们发布与 Emily Bergsland（University of California, San Francisco (UCSF)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment